- Home
- GALT vs OTLK Comparison
GALT vs OTLK Comparison
Compare GALT & OTLK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GALT | OTLK |
|---|---|---|
| Founded | 2000 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 297.0M | 249.6M |
| IPO Year | 2008 | 2016 |
Fundamental Metrics
Financial Performance| Metric | GALT | OTLK |
|---|---|---|
| Price | $3.45 | $1.02 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 4 |
| Target Price | ★ $8.50 | $2.50 |
| AVG Volume (30 Days) | 528.1K | ★ 13.4M |
| Earning Date | 05-15-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 36.84 | ★ 55.91 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $8,146,123.00 |
| Revenue This Year | N/A | $1,430.98 |
| Revenue Next Year | N/A | $173.23 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.03 | $0.16 |
| 52 Week High | $7.13 | $3.39 |
Technical Indicators
Market Signals| Indicator | GALT | OTLK |
|---|---|---|
| Relative Strength Index (RSI) | 43.95 | 41.12 |
| Support Level | $2.75 | $0.75 |
| Resistance Level | $3.35 | $1.83 |
| Average True Range (ATR) | 0.32 | 0.18 |
| MACD | -0.11 | -0.04 |
| Stochastic Oscillator | 28.78 | 18.48 |
Price Performance
Historical ComparisonAbout GALT Galectin Therapeutics Inc.
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.
About OTLK Outlook Therapeutics Inc.
Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA, which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.